Apr
4

Be careful what you buy

A couple weeks ago I used this space to make a few pointed recommendations to entrepreneurs thinking of selling their companies. This week’s news that FairIsaac is selling off its bill review unit reminds us that mistakes can be made on both sides of the deal.
FI merged with/bought out HNC (which included the bill review business and other assets) almost six years ago in a deal that valued HNC at about $240 million.
Reports indicate Mitchell is paying between $10 – $15 million for FI’s bill review unit. While it is impossible (from here) to know how FI valued the bill review part of the deal, there is no doubt a substantial portion of that quarter-billion dollars will have to be written off.
What happened? Why wasn’t FI able to make a go of it in bill review? A couple factors likely contributed to the failure.
First, did FI know what it was buying? Workers comp is a unique and different business with a language and culture all its own. More of a craft industry than a modern business, bill review (as practiced by the vast majority of firms) is as dependent on the expertise and knowledge of processors as it is on the rules and algorithms embedded in applications. (Note it doesn’t have to be, and to my mind should not be, this way – but it is) FI’s business is based on the use of computing power to sort through terabytes of data to find the bits of importance; they may well have discounted the role of the human, which in turn may have led to insufficient emphasis on end-user training.
Second, by several accounts the IT development process at FI was somewhat less than rigorous. Documentation was scarce, schedules were vague, and responsibilities undefined. This led to missed delivery dates and angry customers, a situation that has dramatically improved in the last year or two.
Third, the installation at Texas Mutual was, for a time, a disaster. TM accused FI of overselling and not delivering, and FI countered that TM did not adequately support the installation. TM sued FI for allegedly misrepresenting the application; the suit was settled a few months ago with FI paying Texas Mutual somewhere in the neighborhood of $10 million.
Finally, the BR business was part of the HNC deal, along with decision support technology and other assets; it wasn’t exactly central to the deal, yet FI kept it around. They neither invested in it nor sold it/closed it, with the result that the business was slowly starved. Without attention and investment, it is not surprising that FI’s bill review business had the problems it did.
Lessons? Nothing new here – FI didn’t understand the business it bought, and rather than make a decision to invest in it or blow it up, did nothing. As this became painfully obvious to the unit’s staff, morale plummeted, commitments were missed, and customers angered. Despite all this one of their larger customers, SCIF, is relatively pleased with FI’s work.


Apr
2

UPDATE – FairIsaac confirms sale

There are two leads to this story – FairIsaac confirming what we reported yesterday (their bill review unit was sold to Mitchell International), and an amazingly over-the-top example of corporatespeak.
We’ll do the serious stuff first.
The bill review unit sale will be completed sometime during FI’s Fiscal Q3. The price was not disclosed, but sources indicate it was “not close to eight figures” (FI sold several units for a total price of $65 million).
Approximately 200 FI employees will be affected, and the announcement did not give any clues as to their eventual disposition. We’ll keep you posted.
Now on to the corporatespeak. Here’s a passage that is so bad on so many levels that it is worthy of special consideration…(parens are mine)
“details of a reengineering plan designed to grow revenues (I think they just said that they’ll increase revenues by, wait for it, cutting staff and closing operations…) through strategic resource reallocation (uh, I think they mean tactical, except that doesn’t sound as smart) and improve profitability through significant cost reduction (we’re going to slash our way to profits!). Key components of the plan include rationalizing the business portfolio (dumping businesses we should not have bought in the first place), simplifying management hierarchy (laying off people), eliminating low-priority positions (laying off more people), consolidating facilities and aggressively managing fixed and variable costs.
It is bad enough when your company is sold, but this SAT-word-stuffed run-on justification for dumping a business and firing folks will fool no one, not even the author’s high school English teacher.
FI got out of bill review because they didn’t give the business enough resources and attention, and probably should not have bought it in the first place.


Apr
1

Fair Isaac has sold their bill review business

Fair Isaac will announce today that they have sold their workers comp and auto bill review unit to competitor Mitchell Medical.
And no, this isn’t an April Fool’s prank.
FI has been on the market, with several financial and strategic buyers looking over the property but no firm offers until one was proffered by IME and peer review firm MCN. Sources indicate MCN was the likely buyer, till Mitchell stepped back in (they had previously engaged and withdrawn) and in a matter of days consummated the deal.
The acquisition makes sense strategically; Mitchell dominates the auto claims business, and FI has solid share in WC as well as some auto business. What FI really needs is consistent, reliable investment in its technology, something the parent company was unlikely to continue.
Mitchell will now have a reasonable entre into the WC business, and eliminate one of its competitors for auto bill review.
For FI’s current clients, this is likely good news, as their uncertain future made for difficult decisions. We’ll have to wait and see what changes Mitchell makes; word is the execs (unnamed, to be sure) at FI will be fine. I’m just a bit curious about this; surely they must accept some share of the responsibility for some of the problems that has led to the sale.
Here’s hoping that the non-exec working folks don’t get tossed – not only would that be unfortunate, but there’s a lot of corporate and industry knowledge in those heads that Mitchell will need if it wants to grow the business.


Mar
28

Aetna’s comp network – struggles and progress

My post a few days ago complimenting Aetna on their progress in a number of areas struck a few nerves and elicited more than a few emails from ballistic providers (a couple of the printable ones are in the comment section of that post).
There’s a bit of conflation going on here – my comments were focused on the company’s overall strategy while several critics took the big healthplan to task for it’s poor contracting in workers comp (where the product is Aetna Work Comp Access, or AWCA).
Yet they have valid concerns, concerns that are consistent with problems experienced by Aetna’s WC customers, lousy provider directory data, providers refusing to accept WC patients, heavy handed contracting efforts.
I’ve posted on these issues months ago, yet these issues persist. One provider group in Pennsylvania is so frustrated that they contacted state regulators, only to find out that many other providers had the same problem. Now, they are banding together (albeit informally) and asking regulators to outlaw PPOs in the state.
Other complaints relate to Aetna’s practice of ‘negative affirmation’ (my term, but you can use it). Aetna sends their currently-contracted group health providers a letter stating that unless the provider responds within X days, they will be automatically enrolled in AWCA at their group health rates. In defense of Aetna, their contracts with the providers allow this, as does state law. And providers can opt out at any time, so the damage done is rather limited.
Aetna recently decided to use certified mail instead of regular post when sending these letters to providers – the last batch of letters, some 50,000 in all, went out certified about a month ago. When I discussed this with an Aetna exec, he agreed that the mailing of the negative affirmation letters likely contributed to the provider data issues; AWCA is hopeful that the new certified letter will help.
Still, it is a wonder that it took the big insurer this long. Two big payers view AWCA’s PA data as the worst they have ever encountered. Providers routinely get buckets of mail from networks, and it is certain that many of these ‘negative affirmation’ letters end up in the trash as junk. The WC payers get a contract load from AWCA, construct panels of providers, direct injured workers to these providers, who then either a) don’t accept WC, b) can’t spell WC, c) treat the injured worker and then scream when their bill is slashed and protest to the insurance commissioner et al.
Now that AWCA is the de facto network of choice (due to the Coventry deal), some payers’ concern is there may be little motivation for the company to clean up its act. Even less than it had before the deal was struck and AWCA was working hard to compete with Coventry – now it enjoys near-monopoly status in many states, a condition that some payers think makes it less likely it will invest in provider relations.
That’s not the case, according to AWCA. They are investing in the business – hiring more account managers and provider relations staff and continuing to work on their data issues. They have a ways to go, but appear to be committed to working at it.
If you are sensing a little ambivalence here, you’re right. Payers are notorious for blaming everything on vendors while accepting little responsibility themselves. Vendors suggest improvements in processes and systems that would improve results, only to be told its not a priority for the payer. And part of the negativity about AWCA is undoubtedly from payers that are not holding up their end of the deal.
Yet I expect more from Aetna. They should be better than CorVel and Coventry’s WC division. Here’s hoping they get there, and soon.


Mar
27

Small is beautiful – in workers comp

In my consulting practice, I work with large, really large, and small payers – insurers and self-insured employers, as well as managed care firms – on managed care, claims, and related issues.
One of the best claims-managed care programs I’ve come across is at a relatively tiny insurance company. They have (generally) excellent relations with providers, tightly integrated medical management, claims and bill review, a keen grasp of cost drivers, and highly effective specialty programs. Their network penetration (albeit in a network direction state) is just under 90%.
Their results are impressive.
Medical costs (on a per-claim basis) for lost time claims have dropped dramatically over the last two years. While the industry’s costs were going up by 7.5% (NCCI stats), their clients enjoyed a double-digit decrease in medical expense.
How is this possible? They don’t have access to the actuaries, statisticians, or clinical experts resident at larger payers. They can’t afford expensive IT initiatives, integration projects, and sophisticated rules engine-driven document management processes.
What they do have is focus, an open mind and willingness to try new things, a commitment to do the right thing, and very little patience for bureaucracy. They also have medical folks doing medical management – the adjuster has the final say, but it is rare that the clinician’s recommendation is overturned.
I’m convinced the reason this payer is as successful as they are starts with and is driven by their culture and commitment to doing the right thing. Too often big payers’ plans get bogged down in the cloying mud of committees, process, debate and discussion. Internal rivalries and turf battles suck the life out of promising ideas. Individuals are far more concerned with looking good and checking boxes off their annual goals than actually making sure the programs reduce costs and improve outcomes.
Meanwhile costs continue to go up and care is less than optimal.
What does this mean for you?
It doesn’t have to be that way.


Mar
17

Group health v workers comp

One of the frequent questions from potential investors, regulators, and interested parties is why the group health payers are not doing more in workers comp. With the notable exception of Aetna and Wellpoint, the big group health players’ work comp activity is minimal (and in the case of Wellpoint, just a bit over that threshold).
Many group health execs consider entering into the comp business, figuring that if their company can do so well in group, they should be able to clean up in comp – which is in many ways still in the Dark Ages when it comes to medical management.
Superficially, they are right – but only superficially.
The primary difference is that in comp, the payer cares about the claimant’s functionality – if the injured worker can’t work, the payer is ‘on the hook’ for lost wages as well as medical care. This is not the case in group, where the payer couldn’t care less if the claimant returned to work or is sitting home.

Continue reading Group health v workers comp


Mar
9

Regulators are increasingly seeking politically low-cost ways to reduce workers comp costs. Some have decided to use the Medicaid reimbursement rate for drugs for Workers Comp, evidently figuring that if pharmacies accept it for Medicaid, they’ll do the same for WC. Same ‘logic’ evidently goes for PBMs.
The only problem is it is dead wrong.
1. Unlike Medicaid, there are no copays, restrictive formularies, or other cost- and utilization containment measures. Thus all cost containment efforts in WC for drugs involve resource-intensive Drug Utilization Review processes; pharmacists and clinicians reviewing scripts for appropriateness, medical necessity, potential conflicts and adverse outcomes, and relatedness to the WC medical condition.
2. PBMs pay pharmacies more for WC drugs than for Medicaid drugs; a lot more.
3. Unlike Medicaid, to the extent they exist at all, rebates are much lower in WC. Medicaid rebates are a minimum of 11% of the Average Manufacturer’s Price per unit (and even higher in many states). The rebate revenue significantly reduces states’ costs for drugs. As these rebates are much lower or nonexistent in WC, PBMs do not have rebate dollars to offset their drug costs.
Unlike Medicaid, most workers comp claimants have no idea how WC works, much less who their insurer is; the chances of the claimant presenting with a card is therefore quite low (less than 25% of all WC first fills go to the appropriate PBM). When a Medicaid recipient shows up at a pharmacy, they have been enrolled and thus have a card, and the transaction process is instantaneous and very low cost.
There is no positive enrollment in WC, unless the claimant presents a card, the pharmacy has no way to identify the appropriate PBM. This presents pharmacies with a high level of risk, a level that is not balanced by a reimbursement that makes that risk level tolerable. Specifically;
1. pharmacies are ‘at risk’ for initial fills where they cannot be sure the carrier/employer will accept the claim – this higher risk level requires a higher reimbursement. There is nothing preventing an individual from writing ‘WC’ on a paper script, thereby perpetrating fraud on the pharmacy.
2. the current regs pay pharmacies 25% more for scripts that are ‘controverted’; that is, where the carrier/employer has said they will not (yet) accept the claim
3. The ‘controverted’ situation is very similar to first fills – the carrier/employer has not indicated they will accept the claim, yet the pharmacy is required to fill it, without guarantee of reimbursement
4. the additional risk forced upon the pharmacies may lead them to:
• not fill scripts without a claim number/specific notice from the carrier/employer
• use the claimant’s existing profile (usually a group health PBM card) to fill the script, thereby increasing group health costs
• require the claimant to pay cash which they may, or may not, be able to do
We’re all for reducing work comp medical expense, but the blunt instrument of deep, and inappropriate, cuts in reimbursement for drugs is also counterproductive.
The key driver of prescription drug cost inflation is not the price per pill but utilization – the volume and type of drugs dispensed. The National Council on Compensation Insurance’s recent study on drug costs in workers comp stated “Utilization changes are the driving force in drug cost changes for WC…Utilization is the biggest reason for cost differences between states” (Workers Compensation Prescription Drug Study, 2007 Update; Barry Lipton et al; NCCI, p. 4, 6).
PBMs have adopted and are continuously improving programs designed to address inappropriate utilization. These programs include
• development of clinical evidence-based guidelines for the use of drugs for musculoskeletal injuries
• outreach by PBM physicians in specific cases where the drug treatment plan may be inappropriate
• data mining to identify potentially questionable prescribing patterns including off-label usage of drugs such as Actiq and Fentora
• Prior Authorization of specific drugs (e.g. narcotic opioids, cardiovascular medications).
What does this mean for you?
If PBMs don’t operate in a state or can’t generate any margin, they’ll eliminate any and all utilization control measures.
And drug costs will increase.


Mar
3

Wasted dollars

Alex Swedlow and the good folks at CWCI have published a study that clearly demonstrates the amount of waste in the US health care system, waste generated by nothing other than greed and lousy medicine. While the analysis focused on workers comp, the lessons cross all coverage.
The great thing about workers comp is that unlike health insurance, payers are actually concerned about and financially motivated to ensure claimants get the amount and type of care needed to help them recover and get back to work. And there is a wealth of data to evaluate the effects of medical treatment on RTW.
California changed its workers comp rules a few years ago to limit the number of physical or occupational therapy or chiropractic visits a claimant would get covered by workers comp. The limit was 24 (for each, not together), which all the data suggest is more than adequate to take care of 90%+ of WC medical conditions – surgical or non.
So, what happened?
The average number of PT, OT, or chiro visits per patient dropped by almost half, and the number of patients with more than 24 visits dropped from 30.4% to 9.7% (a decline of 68%). Costs declined dramatically as well.
But did this lead to poorer outcomes?
The results, while encouraging, are not as clear.
While there are data from California that appear to show reductions in the length of disability, the results are muddled by a cap on benefit payments that was also part of the WC reforms. The duration of disability (the length of time claimants were out of work) did decline post-reform. Comparing disability duration two years post-injury, the median length of disability declined by 21.4% (average was down 17.4%).
My sense is the reduction in physical medicine visits contributed to the drop in disability duration – without endless visits to PTs and Chiros to receive ‘care’ that was not helping them recover but merely extending the process, claimants were more likely to be released to return to work.
There’s a lesson here for the non-workers comp world, and policy wonks in particular. It is this – providers overtreat, to the detriment of the patient and the payer. Draconian measures such as flat limits on the amount of treatment do work.
With health reform on the horizon, here’s a great example of the waste in our health care ‘system’, waste that benefits the provider.


Feb
29

CorVel’s financials

I’ve been remiss in not keeping faithful readers up to date on developments at CorVel. I had a chance to listen to their latest earnings call, and here’s the report.
All in all, things are looking up, a bit.
Revenue for the quarter was $76.7 million, up 15.2% from the December 2006 quarter with EPS also improving to $0.43 for the quarter or 61% from the year before.

Continue reading CorVel’s financials


Feb
28

Coventry and PMSI

No, Coventry has not bought PMSI. And I don’t think they will.
As of today, there are still several entities looking at the deal, and as near as I can tell the process is nowhere near complete. Is Coventry looking at PMSI? Probably – as the owner of a competing PBM they’d be foolish not to.
But buying PMSI wouldn’t materially strengthen Coventry’s WC offering. Yes, they’d pick up even more MSA business (which they appear to value); yes, they’d get a major position in the DME/Home health business, but they’d also get a PBM business that is deteriorating, due in no small part to Coventry’s ability to take customers from PMSI.
If I’m Coventry (and both parties are glad that’s not the case) why would I pay a couple hundred million bucks for a property that is deteriorating and I’m beating in the market?
That said, stranger things have happened…